William Mack & Associates
EW icon

William Mack & Associates’s Edwards Lifesciences EW Stock Holding History

William Mack & Associates’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.4K Buy
+178
New +$15.8K ﹤0.01% 355

Other funds holding EW

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $234B AUM 43.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

William Mack & Associates's EW Position: Q3 2026 in Review

William Mack & Associates opened a new position in Edwards Lifesciences (EW) in Q3 2026: 178 shares worth $15.4K. The stake represents ﹤0.01% of the portfolio and ranks #355 among its holdings.

1,141 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • William Mack & Associates held 178 shares of Edwards Lifesciences worth $15.4K as of Q3 2026.
  • Edwards Lifesciences was a new William Mack & Associates position in Q3 2026.
  • Edwards Lifesciences made up ﹤0.01% of William Mack & Associates's portfolio in Q3 2026, its #355 holding.
  • 1,141 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on William Mack & Associates's 13F filing for Q3 2026, filed 27 Oct 2026.